Literature DB >> 32853849

Profile and generation of reduced neuraminidase inhibitor susceptibility in highly pathogenic avian influenza H7N9 virus from human cases in Mainland of China, 2016-2019.

Jing Tang1, Shu-Xia Zhang1, Jing Zhang1, Xi-Yan Li1, Jian-Fang Zhou1, Shu-Mei Zou1, Hong Bo1, Li Xin1, Lei Yang1, Jia Liu1, Wei-Juan Huang1, Jie Dong1, Da-Yan Wang2.   

Abstract

Human infections with highly pathogenic avian influenza (HPAI) H7N9 virus were detected in late 2016. We examined the drug resistance profile of 30 HPAI H7N9 isolates from Mainland of China (2016-2019). Altogether, 23% (7/30) carried neuraminidase inhibitors (NAIs) - resistance mutations, and 13% (4/30) displayed reduced susceptibility to NAIs in neuraminidase (NA) inhibition test. An HPAI H7N9 reassortment virus we prepared was passaged with NAIs for 10 passages. Passage with zanamivir induced an E119G substitution in NA, whereas passage with oseltamivir induced R292K and E119V substitutions that simulated that seen in oseltamivir -treated HPAI H7N9 cases, indicating that the high frequency of resistant strains in the HPAI H7N9 isolates is related to NAIs use. In presence of NAIs, R238I, A146E, G151E and G234T substitutions were found in HA1 region of HA. No amino acid mutations were found in the internal genes of the recombinant virus.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Drug resistance; Highly pathogenic avian influenza H7N9; Influenza virus; Neuraminidase inhibitors

Mesh:

Substances:

Year:  2020        PMID: 32853849     DOI: 10.1016/j.virol.2020.07.018

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  1 in total

1.  Intermolecular Mechanism and Dynamic Investigation of Avian Influenza H7N9 Virus' Susceptibility to E119V-Substituted Peramivir-Neuraminidase Complex.

Authors:  Sphamandla E Mtambo; Samuel C Ugbaja; Aganze G Mushebenge; Bahijjahtu H Abubakar; Mthobisi L Ntuli; Hezekiel M Kumalo
Journal:  Molecules       Date:  2022-03-02       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.